Goodman T, Hajihosseini MK
Nov 06, 2023, 19:00 ET The ultra-small 1cm patch, which only needs to be applied once a week, dramatically increases user convenience Daewoong Therapeutics employs the 'CLOPAM' platform to develop 'advanced formulations,' with plans for commercialization by 2028 CEO Seung-Ho Jeon states, "By developing the GLP-1 analogue patch-type formulation, we aim to meet the unmet needs of patients and medical professionals." SEOUL, South Korea, Nov
Fact : Actually, these drugs are very safe as proven by extensive clinical testing
Daniel Drucker [Biomarker April 2023] To date, the adverse event profile of GLP-1R agonists is characterized by relatively mild gastrointestinal (GI) side effects, such as nausea, vomiting, and diarrhea
They are not meant for purely cosmetic use or short-term crash dieting
This creates a powerful window for change